CGM = continuous glucose monitor(ing)
More affordable, at half the cost of other CGM systems‡4
Easy for you and your patients to use†3,5,6
Features |
Dexcom G7 system |
||
|---|---|---|---|
 Alarms/alerts |
Real-time alarms§ (based on readings every 1 minute) |
Real-time alarms§ (based on readings every 1 minute) |
Real-time alarms (based on readings every 5 minutes)7 |
 Application |
Easy to apply6 using a 1-piece applicator (no in-person patient training required)4 |
Easy to apply†3,5 (no in-person patient training required)4 |
Requires the use of an overpatch7 |
 Glucose reading frequency |
Every minute8
|
Every minute9
|
Every 5 minutes7
|
 App |
Libre app‖
|
Libre app‖
|
Dexcom G7 CGM app
|
 Sensor size |
Smaller than two stacked pennies4
|
Same thickness as two stacked quarters4
|
1.5x thicker than the FreeStyle Libre 3 system4,8
|
 Sensor lifespan |
15 days
|
15 days
|
10 days + 12-hour grace period7
|
 Sensor memory storage |
15 days8
|
8 hours9
|
24 hours7
|
 MBPA or IBOA skin allergens |
No¶
|
No¶
|
Evidence shows IBOA was found in Dexcom G74,10
|
 Sensor MRI compatibility |
Yes#
|
Yes#
|
No
|
IBOA = isobornyl acrylate; MBPA = methylenebisphosphonic acid
FreeStyle Libre 3 system is cleared to be used by children 4 years and older with Libre 3 sensor and 2 years and older with Libre 3 Plus sensor.
FreeStyle Libre 2 system is cleared to be used by children 4 years and older with Libre 2 sensor and 2 years and older with Libre 2 Plus sensor.
The FreeStyle Libre 2 system includes the FreeStyle Libre 2 Plus sensor, FreeStyle Libre 2 sensor, FreeStyle Libre 2 app, Libre App, and the FreeStyle Libre 2 reader.
The FreeStyle Libre 3 system includes the FreeStyle Libre 3 Plus sensor, FreeStyle Libre 3 sensor, FreeStyle Libre 3 app, Libre App, and the FreeStyle Libre 3 reader.
Medicare and other payor criteria may apply.
* Based on retail and durable medical equipment (DME) sales data for patient’s last-filled prescription, by manufacturer.
† Study was performed with the outside US version of the FreeStyle Libre 14 day system. Data is applicable to FreeStyle Libre 2 and 3 systems, as feature sets are similar as FreeStyle Libre 14 day system, excluding alarms.
‡ Based on a comparison of list prices of the FreeStyle Libre personal CGM systems versus competitors’ prescription CGM systems, assuming annual use of one receiver (or equivalent hardware) and quantity of transmitters and/or sensors according to use life. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.
§ Alarm notifications will only be received when alarms settings are enabled and turned on and sensor is within 20 feet (FreeStyle Libre 2 system) or 33 feet (FreeStyle Libre 3 system) unobstructed of the reading device.
‖ The FreeStyle Libre systems apps are only compatible with certain mobile devices and operating systems. Please check the Support section of our website for more information about device compatibility before using the apps. Use of the FreeStyle Libre systems apps may require registration with LibreView.
¶ Not made with these skin allergens. IBOA and MBPA not detected. Test method limit of detection was 0.0016 μg per device for IBOA and 0.0079 μg per device for MBPA.
# MRI Safety Conditions: Sensor readings may be compromised during the MRI, but system function returns fully back to normal after 1 hour. Scanning between the pelvis and sternum (3T scanners) should be limited to 12 minutes maximum with a cooling period of 2 minutes in between scans. All other areas (1.5T scanners) can scan for up to 1 hour continuously without a cooling period.
References: 1. Bolinder, Jan, et al. “Novel Glucose-sensing Technology and Hypoglycaemia in Type 1 Diabetes: a Multicentre, Non-masked, Randomised Controlled Trial.” The Lancet 388, no. 10057 (2016): 2254–2263. https://doi.org/10.1016/S0140-6736(16)31535-5. 2. Evans, Mark, Zoë Welsh, and Alexander Seibold. “Reductions in HbA1c With Flash Glucose Monitoring Are Sustained for up to 24 Months: A Meta-analysis of 75 Real-world Observational Studies.” Diabetes Therapy 13, no. 6 (2022): 1175–1185. https://doi.org/10.1007/s13300-022-01253-9. 3. Haak, Thomas, et al. "Flash Glucose-sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-treated Type 2 Diabetes: a Multicentre, Open-label Randomised Controlled Trial." Diabetes Therapy 8, no. 1 (2017): 55–73. https://doi.org/10.1007/s13300-016-0223-6. 4. Data on file. Abbott Diabetes Care, Inc. 5. Campbell, Fiona M., et al. "Outcomes of Using Flash Glucose Monitoring Technology by Children and Young People With Type 1 Diabetes in a Single Arm Study." Pediatric Diabetes 19, no. 7 (2018): 1294–1301. https://doi.org/10.1111/pedi.12735. 6. Alva, Shridhara, Ronald Brazg, Kristin Castorino, et al. "Accuracy of the Third Generation of a 14-Day Continuous Glucose Monitoring System." Diabetes Therapy 14, no. 4 (2023): 767–776. https://doi.org/10.1007/s13300-023-01385-6. 7. Dexcom G7 CGM User Guide. 8. FreeStyle Libre 3 User's Manual. 9. FreeStyle Libre 2 User's Manual. 10. Mowitz, Martin, et al. “New Device, ‘Old’ Allergens. Allergic Contact Dermatitis Caused by the Dexcom G7 Glucose Sensor.” Contact Dermatitis 90, no. 5 (2024): https://doi.org/10.1111/cod.14514.
ADC-74100 v3.0
Important Safety Information
Failure to use FreeStyle Libre systems as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If glucose reading and alarms (if enabled) do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Get medical attention when appropriate. Abbott Customer Service: 855-632-8658 or visit FreeStyleLibre.us for safety info.
The product images are for illustrative purposes only.
The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott. Other trademarks are the property of their respective owners.
No use of any Abbott trademark, trade name, or trade dress in this site may be made without prior written authorization of Abbott Laboratories, except to identify the product or services of the company.
This website and the information contained herein is intended for use by residents of the United States.
ADC-45115 v21.0
The "Yes" link below will take you out of the Abbott Laboratories family of websites. Links which take you out of Abbott Laboratories worldwide web sites are not under the control of Abbott Laboratories, and Abbott Laboratories is not responsible for the contents of any such site or any further links from such site. Abbott Laboratories is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott Laboratories.
Do you wish to leave this site?
